[go: up one dir, main page]

GB201520057D0 - New therapeutic approaches for demyelinating diseases such as multiple sclerosis - Google Patents

New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Info

Publication number
GB201520057D0
GB201520057D0 GBGB1520057.9A GB201520057A GB201520057D0 GB 201520057 D0 GB201520057 D0 GB 201520057D0 GB 201520057 A GB201520057 A GB 201520057A GB 201520057 D0 GB201520057 D0 GB 201520057D0
Authority
GB
United Kingdom
Prior art keywords
multiple sclerosis
new therapeutic
therapeutic approaches
demyelinating diseases
demyelinating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1520057.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1520057.9A priority Critical patent/GB201520057D0/en
Publication of GB201520057D0 publication Critical patent/GB201520057D0/en
Priority to PCT/EP2016/077501 priority patent/WO2017081296A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1520057.9A 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis Ceased GB201520057D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1520057.9A GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis
PCT/EP2016/077501 WO2017081296A1 (en) 2015-11-13 2016-11-11 New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1520057.9A GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Publications (1)

Publication Number Publication Date
GB201520057D0 true GB201520057D0 (en) 2015-12-30

Family

ID=55132754

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1520057.9A Ceased GB201520057D0 (en) 2015-11-13 2015-11-13 New therapeutic approaches for demyelinating diseases such as multiple sclerosis

Country Status (2)

Country Link
GB (1) GB201520057D0 (en)
WO (1) WO2017081296A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210283163A1 (en) * 2018-07-18 2021-09-16 Duke University Compositions and methods for the treatment of acute and chronic pruritis
EP4434358A4 (en) * 2021-11-16 2025-10-22 House Foods Group Inc Composition for increasing food intake and/or improving anorexia and composition for activating the transient receptor potential ankyrin 1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134075A1 (en) * 2010-04-30 2011-11-03 The University Of Western Ontario Sox9 inhibitors
US9532988B2 (en) * 2013-10-15 2017-01-03 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent

Also Published As

Publication number Publication date
WO2017081296A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
SG11201705093UA (en) Composition for treating il-6-related diseases
SMT201900172T1 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
EP3221004A4 (en) Three-dimensional radiotherapy dose distribution prediction
IL259281B (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
GB201616839D0 (en) Therapeutic compounds
EP3302439A4 (en) Therapeutic composition
IL253461A0 (en) Hydrogels for delivery of therapeutic compounds
GB201415569D0 (en) Therapeutic Compounds
ZA201805046B (en) Therapeutic compounds
HUE043954T2 (en) Multiple sclerosis treatment
GB201716942D0 (en) Therapeutic compounds
EP3283095A4 (en) Therapeutic peptides for cerebrovascular diseases
ZA201607729B (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
GB201617339D0 (en) Therapeutic compounds
IL263821A (en) Therapeutic compounds
GB201416273D0 (en) Therapeutic compounds
GB201520057D0 (en) New therapeutic approaches for demyelinating diseases such as multiple sclerosis
GB201712884D0 (en) Novel therapeutic compounds
EP3294889A4 (en) Multiple sclerosis treatment
EP3125685A4 (en) Producing therapeutic proteins
AU2016210582B2 (en) Peptide for treating inflammatory diseases
GB201712390D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712394D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)